A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Active, not recruiting · NCT04288089 · Registry updated 2026-08-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-08-27 | NCT04288089 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eisai Inc. | 40 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Comprehensive Cancer Centers of Nevada | Las Vegas | United States | 34 |
| Florida Cancer Specialists South - SCRI - PPDS | Sarasota | United States | 1 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Royal Marsden NHS Foundation Trust | Sutton | United Kingdom | 3 |
| Royal Marsden NHS Foundation Trust | London | United Kingdom | 6 |
| Saint Luke's Cancer Institute | Kansas City | United States | 18 |
| Sarah Cannon Research Institute UK - SCRI | London | United Kingdom | 1 |
| Tennessee Oncology, PLLC - SCRI - PPDS | Nashville | United States | 1 |